DOCSLIB.ORG

Altostar® HSV PCR Kit 1.5 09/2020 EN ® Altostar

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Altostar® HSV PCR Kit 1.5 09/2020 EN ® Altostar altona DIAGNOSTICS Instructions for Use AltoStar® HSV PCR Kit 1.5 09/2020 EN ® AltoStar AltoStar® HSV PCR Kit 1.5 For use with CFX96™ Deep Well Dx System (Bio-Rad) AS0061513 96 09 2020 MAN-AS0061510-EN-S02 altona Diagnostics GmbH • Mörkenstr. 12 • D-22767 Hamburg AltoStar® HSV PCR Kit 1.5 Content 1. About these Instructions for Use .............................................................8 2. Intended Use ............................................................................................... 9 3. Kit Content .................................................................................................. 9 4. Storage and Handling .............................................................................. 10 4.1 Storage .................................................................................................10 4.2 Handling ............................................................................................... 11 4.2.1 Master A and Master B .........................................................................12 4.2.2 QS and NTC .........................................................................................12 5. Background Information .........................................................................12 6. Product Description ................................................................................. 13 6.1 Master A and Master B .........................................................................13 6.2 Quantification Standards ......................................................................14 6.3 No Template Control .............................................................................14 6.4 AltoStar® Workflow ...............................................................................14 7. Samples ....................................................................................................15 7.1 Sample Types .......................................................................................15 7.2 Sample Collection and Handling ..........................................................15 7.3 Sample Volume ....................................................................................16 7.4 Sample Tubes.......................................................................................16 7.5 Sample Barcodes .................................................................................16 8. Material and Devices Required, but not Provided ................................ 17 9. Warnings, Precautions and Limitations ................................................. 19 10. Procedure ................................................................................................. 21 10.1 Overview of the AltoStar® Workflow ......................................................21 4 AltoStar® HSV PCR Kit 1.5 10.2 Starting the AltoStar® AM16 ..................................................................25 10.3 Performing Maintenance ......................................................................26 10.4 Programming an AltoStar® Run ............................................................28 10.4.1 Manual Programming ...........................................................................28 10.4.2 Importing from LIMS .............................................................................34 10.5 Creating an AltoStar® Run ....................................................................35 10.6 Starting a Purification Run ....................................................................37 10.6.1 Sample Preparation ..............................................................................38 10.6.1.1 Plasma .......................................................................................38 10.6.2 Preparing Reagents for a Purification Run ........................................... 39 10.6.3 Instrument Loading for a Purification Run ............................................ 40 10.7 During the Purification Run...................................................................50 10.8 End of the Purification Run ...................................................................52 10.9 Purification Run Results .......................................................................55 10.10 Eluate Stability ......................................................................................57 10.10.1 Storage .................................................................................................57 10.10.2 Sealing of the Eluate Plate ...................................................................57 10.10.3 Unsealing of the Eluate Plate ...............................................................59 10.11 Starting a PCR Setup Run....................................................................59 10.12 Preparing Reagents for a PCR Setup Run ........................................... 61 10.12.1 Loading the AltoStar® AM16 for a PCR Setup Run ............................... 62 10.13 During the PCR Setup Run ..................................................................69 10.14 End of the PCR Setup Run...................................................................70 10.15 PCR Setup Run Results .......................................................................72 10.16 Sealing of the PCR Plate ......................................................................74 10.17 PCR Mix Stability ..................................................................................75 10.18 Starting a PCR Run ..............................................................................76 10.19 During the PCR Run .............................................................................79 10.20 Assigning Assays to Well Groups .........................................................80 5 AltoStar® HSV PCR Kit 1.5 10.21 PCR Data Analysis ...............................................................................83 10.21.1 Baseline Correction ..............................................................................84 10.21.2 Exclusion of Irregular PCR Signals ......................................................86 10.21.3 Setting of Thresholds ............................................................................90 10.21.4 Exclusion of Wells Containing Invalid Data .......................................... 93 10.21.4.1 Validity of a Diagnostic PCR Run (qualitative) ........................... 97 10.21.4.2 Validity of a Diagnostic PCR Run (quantitative) ......................... 97 10.21.4.3 Validity of Results for a Sample .................................................. 98 10.21.5 Export of PCR Results for Automated Result Interpretation ................. 99 10.21.6 Export of PCR Results for Manual Result Interpretation .................... 101 10.21.6.1 Manual Interpretation of Results .............................................. 103 11. Disposal ..................................................................................................106 12. Performance Evaluation ........................................................................107 12.1 Plasma................................................................................................107 12.1.1 Analytical Sensitivity ...........................................................................107 12.1.2 Analytical Specificity ...........................................................................109 12.1.2.1 Negative Samples .................................................................... 110 12.1.2.2 Interfering Substances ............................................................. 110 12.1.2.3 Cross Reactivity ........................................................................111 12.1.3 Linear Range ...................................................................................... 112 12.1.4 Precision ............................................................................................. 113 12.1.5 Total Failure Rate ............................................................................... 114 12.1.6 Carry Over .......................................................................................... 115 12.1.7 Diagnostic Evaluation ......................................................................... 115 13. Quality Control ....................................................................................... 119 14. Technical Assistance ............................................................................. 119 15. Literature ................................................................................................. 119 6 AltoStar® HSV PCR Kit 1.5 16. Trademarks and Disclaimers ................................................................120 17. Explanation of Symbols ........................................................................121 7 AltoStar® HSV PCR Kit 1.5 1. About these Instructions for Use These Instructions for Use guide the user in utilizing the AltoStar® HSV PCR Kit 1.5 on the AltoStar® Automation System AM16 (Hamilton; in the following summarized as AltoStar® AM16) with the AltoStar® Connect software (Version 1.6.16 or higher, Hamilton) for automated PCR setup and on the CFX96™ Deep Well Dx System* (Bio-Rad, in the following summarized as CFX96™ DW Dx) with the CFX Manager™ Dx software (Version 3.1, Bio-Rad) for real-time PCR. The main operation steps of the complete "AltoStar® Workflow" (for details see chapter 6.4 AltoStar® Workflow) are described for comprehensibility but without any claim for completeness. For more detailed
Load more

Recommended publications
  • Microtubule-Dependent Trafficking of Alphaherpesviruses in the Nervous
    viruses Review Microtubule-Dependent Trafficking of Alphaherpesviruses in the Nervous System: The Ins and Outs Drishya Diwaker 1 and Duncan W. Wilson 1,2,* 1 Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA; [email protected] 2 Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA * Correspondence: [email protected]; Tel.: +1-(718)-430-2305 Received: 29 November 2019; Accepted: 15 December 2019; Published: 17 December 2019 Abstract: The Alphaherpesvirinae include the neurotropic pathogens herpes simplex virus and varicella zoster virus of humans and pseudorabies virus of swine. These viruses establish lifelong latency in the nuclei of peripheral ganglia, but utilize the peripheral tissues those neurons innervate for productive replication, spread, and transmission. Delivery of virions from replicative pools to the sites of latency requires microtubule-directed retrograde axonal transport from the nerve terminus to the cell body of the sensory neuron. As a corollary, during reactivation newly assembled virions must travel along axonal microtubules in the anterograde direction to return to the nerve terminus and infect peripheral tissues, completing the cycle. Neurotropic alphaherpesviruses can therefore exploit neuronal microtubules and motors for long distance axonal transport, and alternate between periods of sustained plus end- and minus end-directed motion at different stages of their infectious cycle. This review summarizes our current understanding of the molecular details by which this is achieved. Keywords: herpes simplex virus; pseudorabies virus; neurons; anterograde axonal transport; retrograde axonal transport; microtubules; motors 1.
    [Show full text]
  • Where Do We Stand After Decades of Studying Human Cytomegalovirus?
    microorganisms Review Where do we Stand after Decades of Studying Human Cytomegalovirus? 1, 2, 1 1 Francesca Gugliesi y, Alessandra Coscia y, Gloria Griffante , Ganna Galitska , Selina Pasquero 1, Camilla Albano 1 and Matteo Biolatti 1,* 1 Laboratory of Pathogenesis of Viral Infections, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy; [email protected] (F.G.); gloria.griff[email protected] (G.G.); [email protected] (G.G.); [email protected] (S.P.); [email protected] (C.A.) 2 Complex Structure Neonatology Unit, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy; [email protected] * Correspondence: [email protected] These authors contributed equally to this work. y Received: 19 March 2020; Accepted: 5 May 2020; Published: 8 May 2020 Abstract: Human cytomegalovirus (HCMV), a linear double-stranded DNA betaherpesvirus belonging to the family of Herpesviridae, is characterized by widespread seroprevalence, ranging between 56% and 94%, strictly dependent on the socioeconomic background of the country being considered. Typically, HCMV causes asymptomatic infection in the immunocompetent population, while in immunocompromised individuals or when transmitted vertically from the mother to the fetus it leads to systemic disease with severe complications and high mortality rate. Following primary infection, HCMV establishes a state of latency primarily in myeloid cells, from which it can be reactivated by various inflammatory stimuli. Several studies have shown that HCMV, despite being a DNA virus, is highly prone to genetic variability that strongly influences its replication and dissemination rates as well as cellular tropism. In this scenario, the few currently available drugs for the treatment of HCMV infections are characterized by high toxicity, poor oral bioavailability, and emerging resistance.
    [Show full text]
  • Topics in Viral Immunology Bruce Campell Supervisory Patent Examiner Art Unit 1648 IS THIS METHOD OBVIOUS?
    Topics in Viral Immunology Bruce Campell Supervisory Patent Examiner Art Unit 1648 IS THIS METHOD OBVIOUS? Claim: A method of vaccinating against CPV-1 by… Prior art: A method of vaccinating against CPV-2 by [same method as claimed]. 2 HOW ARE VIRUSES CLASSIFIED? Source: Seventh Report of the International Committee on Taxonomy of Viruses (2000) Edited By M.H.V. van Regenmortel, C.M. Fauquet, D.H.L. Bishop, E.B. Carstens, M.K. Estes, S.M. Lemon, J. Maniloff, M.A. Mayo, D. J. McGeoch, C.R. Pringle, R.B. Wickner Virology Division International Union of Microbiological Sciences 3 TAXONOMY - HOW ARE VIRUSES CLASSIFIED? Example: Potyvirus family (Potyviridae) Example: Herpesvirus family (Herpesviridae) 4 Potyviruses Plant viruses Filamentous particles, 650-900 nm + sense, linear ssRNA genome Genome expressed as polyprotein 5 Potyvirus Taxonomy - Traditional Host range Transmission (fungi, aphids, mites, etc.) Symptoms Particle morphology Serology (antibody cross reactivity) 6 Potyviridae Genera Bymovirus – bipartite genome, fungi Rymovirus – monopartite genome, mites Tritimovirus – monopartite genome, mites, wheat Potyvirus – monopartite genome, aphids Ipomovirus – monopartite genome, whiteflies Macluravirus – monopartite genome, aphids, bulbs 7 Potyvirus Taxonomy - Molecular Polyprotein cleavage sites % similarity of coat protein sequences Genomic sequences – many complete genomic sequences, >200 coat protein sequences now available for comparison 8 Coat Protein Sequence Comparison (RNA) 9 Potyviridae Species Bymovirus – 6 species Rymovirus – 4-5 species Tritimovirus – 2 species Potyvirus – 85 – 173 species Ipomovirus – 1-2 species Macluravirus – 2 species 10 Higher Order Virus Taxonomy Nature of genome: RNA or DNA; ds or ss (+/-); linear, circular (supercoiled?) or segmented (number of segments?) Genome size – 11-383 kb Presence of envelope Morphology: spherical, filamentous, isometric, rod, bacilliform, etc.
    [Show full text]
  • Is the ZIKV Congenital Syndrome and Microcephaly Due to Syndemism with Latent Virus Coinfection?
    viruses Review Is the ZIKV Congenital Syndrome and Microcephaly Due to Syndemism with Latent Virus Coinfection? Solène Grayo Institut Pasteur de Guinée, BP 4416 Conakry, Guinea; [email protected] or [email protected] Abstract: The emergence of the Zika virus (ZIKV) mirrors its evolutionary nature and, thus, its ability to grow in diversity or complexity (i.e., related to genome, host response, environment changes, tropism, and pathogenicity), leading to it recently joining the circle of closed congenital pathogens. The causal relation of ZIKV to microcephaly is still a much-debated issue. The identification of outbreak foci being in certain endemic urban areas characterized by a high-density population emphasizes that mixed infections might spearhead the recent appearance of a wide range of diseases that were initially attributed to ZIKV. Globally, such coinfections may have both positive and negative effects on viral replication, tropism, host response, and the viral genome. In other words, the possibility of coinfection may necessitate revisiting what is considered to be known regarding the pathogenesis and epidemiology of ZIKV diseases. ZIKV viral coinfections are already being reported with other arboviruses (e.g., chikungunya virus (CHIKV) and dengue virus (DENV)) as well as congenital pathogens (e.g., human immunodeficiency virus (HIV) and cytomegalovirus (HCMV)). However, descriptions of human latent viruses and their impacts on ZIKV disease outcomes in hosts are currently lacking. This review proposes to select some interesting human latent viruses (i.e., herpes simplex virus 2 (HSV-2), Epstein–Barr virus (EBV), human herpesvirus 6 (HHV-6), human parvovirus B19 (B19V), and human papillomavirus (HPV)), whose virological features and Citation: Grayo, S.
    [Show full text]
  • Aujeszky's Disease Control in Pigs? Cattle Exposed to Asymptomatically Infected Pigs
    Aujeszky’s Importance Aujeszky’s disease (pseudorabies) is a highly contagious, economically significant Disease disease of pigs. This viral infection tends to cause central nervous system (CNS) signs in young animals, respiratory illness in older pigs, and reproductive losses in sows. Pseudorabies, Mad Itch Mortality rates in very young piglets can be high, although older animals typically recover. Recovered swine can carry the virus latently, and may resume shedding it at a later time. Other species can be infected when they contact infected pigs or eat raw Last Updated: January 2017 porcine tissues, resulting in neurological signs that are usually fatal within a few days. Serious outbreaks were seen in cattle exposed to infected swine in the past, and thousands of farmed mink and foxes in China recently died after being fed contaminated pig liver. Why animals other than pigs do not typically survive this infection is not clear. Aujeszky’s disease can result in trade restrictions, as well as economic losses, in countries where it is endemic. It remains a significant problem among domesticated pigs in some parts of the world. Variants that recently caused outbreaks among vaccinated pigs in China may be a particular concern. Eradication programs have eliminated this disease from domesticated swine in many nations, including the U.S.. The disease has never been reported in Canada. However, viruses are often still maintained in feral pigs and wild boar, and could be reintroduced to domesticated pigs from this source. Viruses from wild suids have also sporadically caused Aujeszky’s disease in other animals, particularly hunting dogs.
    [Show full text]
  • Herpesviral Latency—Common Themes
    pathogens Review Herpesviral Latency—Common Themes Magdalena Weidner-Glunde * , Ewa Kruminis-Kaszkiel and Mamata Savanagouder Department of Reproductive Immunology and Pathology, Institute of Animal Reproduction and Food Research of Polish Academy of Sciences, Tuwima Str. 10, 10-748 Olsztyn, Poland; [email protected] (E.K.-K.); [email protected] (M.S.) * Correspondence: [email protected] Received: 22 January 2020; Accepted: 14 February 2020; Published: 15 February 2020 Abstract: Latency establishment is the hallmark feature of herpesviruses, a group of viruses, of which nine are known to infect humans. They have co-evolved alongside their hosts, and mastered manipulation of cellular pathways and tweaking various processes to their advantage. As a result, they are very well adapted to persistence. The members of the three subfamilies belonging to the family Herpesviridae differ with regard to cell tropism, target cells for the latent reservoir, and characteristics of the infection. The mechanisms governing the latent state also seem quite different. Our knowledge about latency is most complete for the gammaherpesviruses due to previously missing adequate latency models for the alpha and beta-herpesviruses. Nevertheless, with advances in cell biology and the availability of appropriate cell-culture and animal models, the common features of the latency in the different subfamilies began to emerge. Three criteria have been set forth to define latency and differentiate it from persistent or abortive infection: 1) persistence of the viral genome, 2) limited viral gene expression with no viral particle production, and 3) the ability to reactivate to a lytic cycle. This review discusses these criteria for each of the subfamilies and highlights the common strategies adopted by herpesviruses to establish latency.
    [Show full text]
  • Herpes Simplex Virus 1 (HSV-1) for Cancer Treatment Y Shen and J Nemunaitis Mary Crowley Medical Research Center, Dallas, TX, USA
    Cancer Gene Therapy (2006) 13, 975–992 r 2006 Nature Publishing Group All rights reserved 0929-1903/06 $30.00 www.nature.com/cgt REVIEW Herpes simplex virus 1 (HSV-1) for cancer treatment Y Shen and J Nemunaitis Mary Crowley Medical Research Center, Dallas, TX, USA Cancer remains a serious threat to human health, causing over 500 000 deaths each year in US alone, exceeded only by heart diseases. Many new technologies are being developed to fight cancer, among which are gene therapies and oncolytic virotherapies. Herpes simplex virus type 1 (HSV-1) is a neurotropic DNA virus with many favorable properties both as a delivery vector for cancer therapeutic genes and as a backbone for oncolytic viruses. Herpes simplex virus type 1 is highly infectious, so HSV-1 vectors are efficient vehicles for the delivery of exogenous genetic materials to cells. The inherent cytotoxicity of this virus, if harnessed and made to be selective by genetic manipulations, makes this virus a good candidate for developing viral oncolytic approach. Furthermore, its large genome size, ability to infect cells with a high degree of efficiency, and the presence of an inherent replication controlling mechanism, the thymidine kinase gene, add to its potential capabilities. This review briefly summarizes the biology of HSV-1, examines various strategies that have been used to genetically modify the virus, and discusses preclinical as well as clinical results of the HSV-1-derived vectors in cancer treatment. Cancer Gene Therapy (2006) 13, 975–992. doi:10.1038/sj.cgt.7700946; published online 7 April 2006 Keywords: herpes simplex virus; HSV-1; cancer; oncolytic virus; clinical; gene therapy Introduction anti-HSV antibodies during the replication process.
    [Show full text]
  • Complete Sections As Applicable
    This form should be used for all taxonomic proposals. Please complete all those modules that are applicable (and then delete the unwanted sections). For guidance, see the notes written in blue and the separate document “Help with completing a taxonomic proposal” Please try to keep related proposals within a single document; you can copy the modules to create more than one genus within a new family, for example. MODULE 1: TITLE, AUTHORS, etc (to be completed by ICTV Code assigned: 2010.016a-eV officers) Short title: Create genus Scutavirus (type species: the currently unassigned species Chelonid herpesvirus 5) in subfamily Alphaherpesvirinae, family Herpesviridae (e.g. 6 new species in the genus Zetavirus) Modules attached 1 2 3 4 5 (modules 1 and 9 are required) 6 7 8 9 Author(s) with e-mail address(es) of the proposer: Andrew Davison ([email protected]) & Duncan McGeoch List the ICTV study group(s) that have seen this proposal: A list of study groups and contacts is provided at http://www.ictvonline.org/subcommittees.asp . If in doubt, contact the appropriate subcommittee Herpesvirales Study Group chair (fungal, invertebrate, plant, prokaryote or vertebrate viruses) ICTV-EC or Study Group comments and response of the proposer: This proposal has had a full round of discussion and has been approved without dissent by the Herpesvirales Study Group. Date first submitted to ICTV: To Study Group Chair Feb. 3, 2010 Communicated to SG Feb. 9, 2010 Final SG vote completed April 7, 2010 Date of this revision (if different to above): June 4, 2010 Module 7 added July 4, 2010 Page 1 of 6 MODULE 3: NEW GENUS creating a new genus Ideally, a genus should be placed within a higher taxon.
    [Show full text]
  • ® Parvovirinae ® Densovirinae
    Parvovirinae humans can be infected by viruses within three other genera from the family Parvoviridae. Parvovirus B19 Bocaviruses Dependoviruses(Adeno-Associated Virus) Densovirinae Autonomous parvovirus replication Helper dependent parvovirus (AAV) replication Infection with adenovirus Infection without adenovirus Lytic replication Superinfect with adenovirus AAV DNA integrates into chromosome 19 Erythema Infectiosum (fifth disease) Arthritis Transient Aplastic Crisis in chronic hemolytic anemia Chronic anemia in immunodeficiency syndrome Hydrops fetalis Fifth disease is a mild rash illness that occurs most commonly in children An ill child may have a low-grade fever, malaise, or a "cold" a few days before the rash breaks out The child is usually not very ill, and the rash resolves in 7 to 10 days. Transmission of infection occurs via: respiratory secretions (e.g., saliva, sputum, or nasal mucus) The virus is probably spread from person to person by direct contact with those secretions blood-derived products administered parenterally vertically from mother to fetus How soon after infection with parvovirus B19 does a person become ill A susceptible person usually becomes ill 4 to 14 days after being infected with the virus, but may become ill for as long as 20 days after infection. Does everyone who is infected with parvovirus B19 become ill? No. During outbreaks of fifth disease, about 20% of adults and children who are infected with parvovirus B19 do not develop any symptoms. Furthermore, other persons infected with the virus will have a non-specific illness that is not characteristic of fifth disease. Persons infected with the virus, however, do develop lasting immunity that protects them against infection in the future.
    [Show full text]
  • REGULATION of ALPHA-HERPESVIRUS REACTIVATION from LATENCY by STRESS Insun Kook University of Nebraska - Lincoln, [email protected]
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Dissertations & Theses in Veterinary and Veterinary and Biomedical Sciences, Department of Biomedical Science 12-2016 REGULATION OF ALPHA-HERPESVIRUS REACTIVATION FROM LATENCY BY STRESS Insun Kook University of Nebraska - Lincoln, [email protected] Follow this and additional works at: http://digitalcommons.unl.edu/vetscidiss Part of the Animal Diseases Commons, Life Sciences Commons, Veterinary Medicine Commons, and the Virus Diseases Commons Kook, Insun, "REGULATION OF ALPHA-HERPESVIRUS REACTIVATION FROM LATENCY BY STRESS" (2016). Dissertations & Theses in Veterinary and Biomedical Science. 21. http://digitalcommons.unl.edu/vetscidiss/21 This Article is brought to you for free and open access by the Veterinary and Biomedical Sciences, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Dissertations & Theses in Veterinary and Biomedical Science by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. REGULATION OF ALPHA-HERPESVIRUS REACTIVATION FROM LATENCY BY STRESS by Insun Kook A DISSERTATION Presented to the Faculty of The Graduate College at the University of Nebraska In Partial Fulfillment of Requirements For the Degree of Doctor of Philosophy Major: Integrative Biomedical Sciences Under the Supervision of Professor Clinton Jones Lincoln, Nebraska December, 2016 REGULATION OF ALPHA-HERPESVIRUS REACTIVATION FROM LATENCY BY STRESS Insun Kook, Ph.D. University of Nebraska, 2016 Advisor: Clinton Jones Bovine herpes virus 1 (BHV-1) and Herpes simplex virus 1 (HSV-1) are crucial etiological viral agent of clinical diseases. HSV-1 and BHV-1 establish latent infection in sensory neurons. Periodically, reactivation from latency occurs resulting in virus excretion and transmission.
    [Show full text]
  • Supporting Information
    Supporting Information Wu et al. 10.1073/pnas.0905115106 20 15 10 5 0 10 15 20 25 30 35 40 Fig. S1. HGT cutoff and tree topology. Robinson-Foulds (RF) distance [Robinson DF, Foulds LR (1981) Math Biosci 53:131–147] between viral proteome trees with different horizontal gene transfer (HGT) cutoffs h at feature length 8. Tree distances are between h and h-1. The tree topology remains stable for h in the range 13–31. We use h ϭ 20 in this work. Wu et al. www.pnas.org/cgi/content/short/0905115106 1of6 20 18 16 14 12 10 8 6 0.0/0.5 0.5/0.7 0.7/0.9 0.9/1.1 1.1/1.3 1.3/1.5 Fig. S2. Low complexity features and tree topology. Robinson-Foulds (RF) distance between viral proteome trees with different low-complexity cutoffs K2 for feature length 8 and HGT cutoff 20. The tree topology changes least for K2 ϭ 0.9, 1.1 and 1.3. We choose K2 ϭ 1.1 for this study. Wu et al. www.pnas.org/cgi/content/short/0905115106 2of6 Table S1. Distribution of the 164 inter-viral-family HGT instances bro hr RR2 RR1 IL-10 Ubi TS Photol. Total Baculo 45 1 10 9 11 1 77 Asco 11 7 1 19 Nudi 1 1 1 3 SGHV 1 1 2 Nima 1 1 2 Herpes 48 12 Pox 18 8 2 3 1 3 35 Irido 1 1 2 4 Phyco 2 3 2 1 8 Allo 1 1 2 Total 56 8 35 24 6 17 14 4 164 The HGT cutoff is 20 8-mers.
    [Show full text]
  • Altostar® VZV PCR Kit 1.5 09/2020 EN ® Altostar
    altona DIAGNOSTICS Instructions for Use AltoStar® VZV PCR Kit 1.5 09/2020 EN ® AltoStar AltoStar® VZV PCR Kit 1.5 For use with CFX96™ Deep Well Dx System (Bio-Rad) AS0071513 96 09 2020 MAN-AS0071510-EN-S02 altona Diagnostics GmbH • Mörkenstr. 12 • D-22767 Hamburg AltoStar® VZV PCR Kit 1.5 Content 1. About these Instructions for Use .............................................................8 2. Intended Use ............................................................................................... 9 3. Kit Content .................................................................................................. 9 4. Storage and Handling .............................................................................. 10 4.1 Storage .................................................................................................10 4.2 Handling ............................................................................................... 11 4.2.1 Master A and Master B .........................................................................12 4.2.2 QS and NTC .........................................................................................12 5. Background Information .........................................................................13 6. Product Description ................................................................................. 13 6.1 Master A and Master B .........................................................................14 6.2 Quantification Standards ......................................................................14
    [Show full text]